NEW YORK – NeoGenomics announced on Tuesday a partnership with Lilly Oncology aimed at molecular testing for thyroid cancer patients.
Through the Thyroid Cancer Testing Program, sponsored by Lilly Oncology, NeoGenomics will offer patients in the program either the NGS Thyroid Profile test for metastatic medullary thyroid cancer patients, or the NGS Thyroid Profile plus RET FISH test for non-metastatic medullary thyroid cancer patients.